---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-23-000044"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T13:57:34.284991+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q3 net loss $0.39/sh; cash $140.8M; obesity trial readout Q4 2023

## Summary
- Net loss $20.7M ($0.39/sh) vs $23.5M ($0.48) in Q3 2022.
- Cash, equivalents & short-term investments $140.8M as of Sep 30, 2023.
- Top-line 48-week MOMENTUM Phase 2 obesity trial data expected Q4 2023; 391 subjects randomized.
- HepTcell Phase 2 CHB top-line results anticipated Q1 2024; ~80 subjects enrolled.
- Pemvidutide granted Fast Track for NASH; IMPACT Phase 2b enrollment ongoing; results Q1 2025.

## SEC filing metadata
- accession: 0001326190-23-000044
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000044/0001326190-23-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000044/alt-20231107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-23-000044
- JSON: https://secwatch.observer/filing/0001326190-23-000044.json
- Plain text: https://secwatch.observer/filing/0001326190-23-000044.txt

## Key facts
- Earnings Releases
  Altimmune, Inc. reported the three months ended September 30, 2023 results: net income $20.7 million, or $0.39 net loss per share, EPS $0.39 net loss per share.
  - Period: the three months ended September 30, 2023
  - Net income: $20.7 million, or $0.39 net loss per share
  - EPS: $0.39 net loss per share
  - Result: reported results
  source text: Net loss for the three months ended September 30, 2023 was $20.7 million, or $0.39 net loss per share, compared to a net loss of $23.5 million, or $0.48 net loss per share, in the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000044/0001326190-23-000044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.